https://cyanatx.com/
Cyana Therapeutics | Precision Immuno-Oncology | ENPP1 Inhibitor Cancer Therapy
Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open,...
immuno oncologytherapeuticsprecisioninhibitorcancer
https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1105381/full
Frontiers | Case report: A rare homozygous variation in the ENPP1 gene, presenting with generalized...
Generalized arterial calcification of infancy (GACI) is a rare genetic disease characterized by arterial calcifications or stenoses and hypertension. GACI is...
https://www.stingraytx.com/
Stingray Therapeutics | Best-in-Class ENPP1 Inhibitor for Cancer Immunotherapy
Stingray Therapeutics is developing Vizenpistat (SR-8541A), the world's most advanced ENPP1 inhibitor — in active clinical trials with a strong safety profile...
best in classstingraytherapeuticsinhibitorcancer
https://pubmed.ncbi.nlm.nih.gov/17228024/
The Q121/Q121 genotype of ENPP1/PC-1 is associated with lower BMI in non-diabetic whites
This study investigated the role of the ENPP1/PC-1 gene K121Q polymorphism in predicting BMI (kg/m2) in non-diabetic individuals. Three independent samples (n...
https://www.ncbi.nlm.nih.gov/nuccore/NM_006208
Homo sapiens ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1 - Nucleotide - NCBI
homo sapiensphosphodiesterasenucleotidencbi